Description
Looking for kids, teens, and young adults with With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)for a study of an investigational drug combination help people feel better, have fewer side effects, and prevent cancer from returning.
Overview
Participants in this study will receive the immunotherapy medicine blinatumomab in addition to chemotherapy plus dasatinib or imatinib. The treatment on this study takes about 2 years. It is divided into 7-8 phases of therapy
What we're hoping for
We are studying if adding a new drug to the usual medicine for Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) reduces side effects and prevents cancer returning.
Additional Information
ClinicalTrials.gov Identifier: NCT06124157